Biotech Values

[ghmm]

FOLD:
Agree on the EU. I may be mistaken but I think the post hoc is not as bad as it may seem I think it is those having one of the mutations that responds to Amigal (I believe they Estimate about 50% of Fabry patienst a little higher in the late onset patients which I suspect may be much, much higher based not only on what Amicus has said but TKT also).

Edit: Should add that the Phase 3 always them to screen for response too.